A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

Exclusion Criteria

• •Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease
• •Has uncontrolled significant cardiovascular disease or cerebrovascular disease
• •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing
• •Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage
• •Is HIV-positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• •Known additional malignancy that is progressing or has required active treatment within the past 2 years
• •Known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Active infection requiring systemic therapy, with exceptions
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has HBV or HCV infection